Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.

Zini R, Guglielmelli P, Pietra D, Rumi E, Rossi C, Rontauroli S, Genovese E, Fanelli T, Calabresi L, Bianchi E, Salati S, Cazzola M, Tagliafico E, Vannucchi AM, Manfredini R; AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators.

Blood Cancer J. 2017 Dec 8;7(12):638. doi: 10.1038/s41408-017-0010-2.

2.

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis.

Li B, Gale RP, Xu Z, Qin T, Song Z, Zhang P, Bai J, Zhang L, Zhang Y, Liu J, Huang G, Xiao Z.

J Hematol Oncol. 2017 May 2;10(1):99. doi: 10.1186/s13045-017-0472-5.

3.

Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis.

Song J, Hussaini M, Zhang H, Shao H, Qin D, Zhang X, Ma Z, Hussnain Naqvi SM, Zhang L, Moscinski LC.

Am J Clin Pathol. 2017 May 1;147(5):444-452. doi: 10.1093/ajcp/aqw222.

4.

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.

Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A.

J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.

5.

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Rumi E, Cazzola M.

Blood. 2017 Feb 9;129(6):680-692. doi: 10.1182/blood-2016-10-695957. Epub 2016 Dec 27. Review.

6.

The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.

Chen Y, Fang F, Hu Y, Liu Q, Bu D, Tan M, Wu L, Zhu P.

PLoS One. 2016 Apr 25;11(4):e0154183. doi: 10.1371/journal.pone.0154183. eCollection 2016.

7.

Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.

Soyer N, Haznedaroğlu İC, Cömert M, Çekdemir D, Yılmaz M, Ünal A, Çağlıyan G, Bilgir O, İlhan O, Özdemirkıran F, Kaya E, Şahin F, Vural F, Saydam G.

Turk J Haematol. 2017 Mar 1;34(1):27-33. doi: 10.4274/tjh.2016.0005. Epub 2016 Apr 18.

8.

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).

Zhao S, Zhang X, Xu Y, Feng Y, Sheng W, Cen J, Wu D, Han Y.

Int J Med Sci. 2016 Jan 25;13(1):85-91. doi: 10.7150/ijms.10539. eCollection 2016.

9.

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Barbui T, Thiele J, Vannucchi AM, Tefferi A.

Blood Cancer J. 2015 Aug 14;5:e337. doi: 10.1038/bcj.2015.64. Review.

10.
11.

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.

Hermouet S, Bigot-Corbel E, Gardie B.

Mediators Inflamm. 2015;2015:145293. doi: 10.1155/2015/145293. Epub 2015 Oct 11. Review.

12.

Mutational analysis of SH2B3 in Korean patients with BCR-ABL1 negative myeloproliferative neoplasm.

Kim N, Kim IS, Chang CL, Lee EY, Kim HH, Song MK, Shin HJ, Chung JS.

Ann Lab Med. 2016 Jan;36(1):67-9. doi: 10.3343/alm.2016.36.1.67. No abstract available.

13.

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.

Čokić VP, Mitrović-Ajtić O, Beleslin-Čokić BB, Marković D, Buač M, Diklić M, Kraguljac-Kurtović N, Damjanović S, Milenković P, Gotić M, Raj PK.

Mediators Inflamm. 2015;2015:453020. doi: 10.1155/2015/453020. Epub 2015 Sep 29.

14.

Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.

Todisco G, Manshouri T, Verstovsek S, Masarova L, Pierce SA, Keating MJ, Estrov Z.

Leuk Lymphoma. 2016 May;57(5):1054-9. doi: 10.3109/10428194.2015.1092527. Epub 2015 Oct 19.

15.

Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.

Guo H, Chen X, Tian R, Chang J, Li J, Tan Y, Xu Z, Ren F, Zhao J, Pan J, Zhang N, Wang X, He J, Yang W, Wang H.

PLoS One. 2015 Sep 16;10(9):e0138250. doi: 10.1371/journal.pone.0138250. eCollection 2015. Erratum in: PLoS One. 2015;10(10):e0141173.

16.
17.

Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients.

Michiels JJ.

World J Crit Care Med. 2015 Aug 4;4(3):230-9. doi: 10.5492/wjccm.v4.i3.230. eCollection 2015 Aug 4. Review.

18.

JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.

Debeurme F, Lacout C, Moratal C, Bagley RG, Vainchenker W, Adrian F, Villeval JL.

J Cell Mol Med. 2015 Nov;19(11):2564-74. doi: 10.1111/jcmm.12608. Epub 2015 Jul 14.

19.

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.

Yönal İ, Dağlar-Aday A, Akadam-Teker B, Yılmaz C, Nalçacı M, Yavuz AS, Sargın FD.

Turk J Haematol. 2016 Jun 5;33(2):94-101. doi: 10.4274/tjh.2014.0136. Epub 2015 Apr 27.

20.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC.

Nat Commun. 2015 Apr 7;6:6691. doi: 10.1038/ncomms7691.

Supplemental Content

Loading ...
Support Center